Basic Information
| LncRNA/CircRNA Name | MIR222HG |
| Synonyms | NA |
| Region | GRCh38_X:45745211-45770274 |
| Ensemble | ENSG00000270069 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, luciferase reporter assay, RIP, in vitro knockdown etc. |
| Sample | cell line (LNCaP, LNCaP-Abl), PCa tumor tissues |
| Expression Pattern | up-regulated |
| Function Description | Upon promoter activation, a set of polyadenylated long non-coding RNA (lncRNA) MIR222HGs was transcribed from this promoter region. Over-expression of these MIR222HGs increased androgen-independent cell growth and repressed the expression of androgen receptor-regulated dihydrotestosterone (DHT)-induced KLK3, TMPRSS2, and FKBP5 in HSPC LNCaP cells, hallmarks of the CRPC phenotype. Clinically, increased expression of MIR222HG is associated with PCa progression to CRPC.MIR222HG may potentially affect miR-mediated expression silencing, subsequently leading to AR reprogramming. Our study highlights an essential role of a non-coding RNA in CRPC development and that differential activation of a single promoter can up-regulate two different types of non-coding RNAs, miR-221/222 and lncRNA MIR222HG, in CRPC. |
| Pubmed ID | 29540675 |
| Year | 2018 |
| Title | Expression of lncRNA MIR222HG co tra Source Oncogenesis SO 2018 Mar 13 7 3 30[PMIDT29540675] |
External Links
| Links for MIR222HG | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |